Muhammad Hussain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammad Hussain has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Hassan
Department of Medicine Dow University of Health Sciences Karachi Pakistan
10 shared publications - Saifullah Khan
Department of Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
7 shared publications - Faizan Ahmed
Department of Internal Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA
5 shared publications - Haris Bin Tahir
Lahore General Hospital, Lahore, Pakistan
5 shared publications - Najam Gohar
Department of Internal Medicine, Ameeruddin Medical College, Post Graduate Medical Institute, Lahore 54000, Pakistan
5 shared publications - Tehmasp Rehman Mirza
Department of Internal Medicine, Shalamar Medical and Dental College, Lahore 54840, Pakistan
5 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (10) , e71831
Comparative Effectiveness of Intravenous Tenecteplase versus Alteplase in Posterior Circulation Ischemic Stroke: A Systematic Review and Meta‐Analysis
Background: Posterior circulation ischemic stroke (PCIS) is associated with substantial morbidity and mortality, and the optimal intravenous thrombolytic strategy in this subgroup remains unclear. Methods: We searched databases for studies comparing intravenous tenecteplase with alteplase in adults with PCIS. The primary outcome was functional independence at 90 days (mRS 0–2). Secondary outcomes included other functional outcomes, reperfusion, hemorrhagic complications, and mortality. Results: Five studies involving 997 patients were included. Regarding efficacy outcomes, tenecteplase was associated with a significantly greater likelihood of achieving an ambulatory functional outcome at 90 days (mRS 0–3) [RR 1.29, 95% CI 1.03–1.60; p = 0.02] and improved pre‐EVT perfusion [RR 2.18, 95% CI 1.06–4.46; p = 0.03]. No significant differences were observed for excellent functional outcome (mRS 0–1) [RR 1.19, 95% CI 0.91–1.56; p = 0.20], functional independence (mRS 0–2) [RR 1.10, 95% CI 0.89–1.37; p = 0.39], or post‐EVT perfusion [RR 1.12, 95% CI 0.89–1.40; p = 0.34]. Regarding safety outcomes, no significant differences were observed between tenecteplase and alteplase for symptomatic intracranial hemorrhage (sICH) [RR 0.89, 95% CI 0.36–2.22; p = 0.81], any intracranial hemorrhage [RR 1.02, 95% CI 0.59–1.78; p = 0.94], parenchymal hematoma [RR 0.76, 95% CI 0.24–2.38; p = 0.64], or 90‐day mortality [RR 0.88, 95% CI 0.66–1.17; p = 0.39]. Conclusion: Tenecteplase may improve reperfusion and ambulatory recovery without increasing hemorrhagic complications or mortality compared with alteplase in PCIS, although larger PCIS‐specific studies are needed.
- 8 October 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (10) , e71831
Open AccessComparative Effectiveness of Intravenous Tenecteplase versus Alteplase in Posterior Circulation Ischemic Stroke: A Systematic Review and Meta‐Analysis
Background: Posterior circulation ischemic stroke (PCIS) is associated with substantial morbidity and mortality, and the optimal intravenous thrombolytic strategy in this subgroup remains unclear. Methods: We searched databases for studies comparing intravenous tenecteplase with alteplase in adults with PCIS. The primary outcome was functional independence at 90 days (mRS 0–2). Secondary outcomes included other functional outcomes, reperfusion, hemorrhagic complications, and mortality. Results: Five studies involving 997 patients were included. Regarding efficacy outcomes, tenecteplase was associated with a significantly greater likelihood of achieving an ambulatory functional outcome at 90 days (mRS 0–3) [RR 1.29, 95% CI 1.03–1.60; p = 0.02] and improved pre‐EVT perfusion [RR 2.18, 95% CI 1.06–4.46; p = 0.03]. No significant differences were observed for excellent functional outcome (mRS 0–1) [RR 1.19, 95% CI 0.91–1.56; p = 0.20], functional independence (mRS 0–2) [RR 1.10, 95% CI 0.89–1.37; p = 0.39], or post‐EVT perfusion [RR 1.12, 95% CI 0.89–1.40; p = 0.34]. Regarding safety outcomes, no significant differences were observed between tenecteplase and alteplase for symptomatic intracranial hemorrhage (sICH) [RR 0.89, 95% CI 0.36–2.22; p = 0.81], any intracranial hemorrhage [RR 1.02, 95% CI 0.59–1.78; p = 0.94], parenchymal hematoma [RR 0.76, 95% CI 0.24–2.38; p = 0.64], or 90‐day mortality [RR 0.88, 95% CI 0.66–1.17; p = 0.39]. Conclusion: Tenecteplase may improve reperfusion and ambulatory recovery without increasing hemorrhagic complications or mortality compared with alteplase in PCIS, although larger PCIS‐specific studies are needed.
- 16 September 2026
- Published by Wolters Kluwer Health in Cardiology in Review
Effect of Aromatherapy on Anxiety and Physiological Parameters in Patients Undergoing Coronary Angiography
Anxiety is common among patients undergoing coronary angiography and may adversely affect physiological stability and procedural outcomes. Although pharmacological anxiolytics are commonly used, they may be associated with undesirable adverse effects. Aromatherapy has been proposed as a complementary intervention with potential anxiolytic benefits. This systematic review and meta-analysis evaluated the effectiveness of inhalational aromatherapy in reducing anxiety and improving physiological parameters in patients undergoing coronary angiography. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and registered in the International Prospective Register of Systematic Reviews (CRD420261329600). A comprehensive search of PubMed/MEDLINE, Embase, Scopus, and Cochrane CENTRAL was performed from database inception to October 2025. Randomized controlled trials comparing inhalational aromatherapy with standard care or placebo before coronary angiography were included. Outcomes of interest were anxiety scores, systolic and diastolic blood pressure, heart rate, and respiratory rate. Data were pooled using a random-effects model and reported as standardized mean differences (SMDs) or mean differences with 95% confidence intervals (CIs). Three randomized controlled trials involving 274 participants met the inclusion criteria. Baseline anxiety levels were comparable between the aromatherapy and control groups (SMD 0.06, 95% CI −0.18 to 0.30; I 2 = 3%). Aromatherapy significantly reduced postprocedural anxiety (SMD −0.66, 95% CI −1.20 to −0.13; I 2 = 79%). No statistically significant differences were observed between groups in systolic blood pressure, diastolic blood pressure, heart rate, or respiratory rate. These findings suggest that aromatherapy may be an effective complementary intervention for reducing anxiety in patients undergoing coronary angiography, although its effects on physiological parameters remain uncertain. Larger, high-quality randomized controlled trials are needed to confirm these findings.
- 16 September 2026
- Published by Wolters Kluwer Health in Cardiology in Review
Effect of Aromatherapy on Anxiety and Physiological Parameters in Patients Undergoing Coronary Angiography
Anxiety is common among patients undergoing coronary angiography and may adversely affect physiological stability and procedural outcomes. Although pharmacological anxiolytics are commonly used, they may be associated with undesirable adverse effects. Aromatherapy has been proposed as a complementary intervention with potential anxiolytic benefits. This systematic review and meta-analysis evaluated the effectiveness of inhalational aromatherapy in reducing anxiety and improving physiological parameters in patients undergoing coronary angiography. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and registered in the International Prospective Register of Systematic Reviews (CRD420261329600). A comprehensive search of PubMed/MEDLINE, Embase, Scopus, and Cochrane CENTRAL was performed from database inception to October 2025. Randomized controlled trials comparing inhalational aromatherapy with standard care or placebo before coronary angiography were included. Outcomes of interest were anxiety scores, systolic and diastolic blood pressure, heart rate, and respiratory rate. Data were pooled using a random-effects model and reported as standardized mean differences (SMDs) or mean differences with 95% confidence intervals (CIs). Three randomized controlled trials involving 274 participants met the inclusion criteria. Baseline anxiety levels were comparable between the aromatherapy and control groups (SMD 0.06, 95% CI −0.18 to 0.30; I 2 = 3%). Aromatherapy significantly reduced postprocedural anxiety (SMD −0.66, 95% CI −1.20 to −0.13; I 2 = 79%). No statistically significant differences were observed between groups in systolic blood pressure, diastolic blood pressure, heart rate, or respiratory rate. These findings suggest that aromatherapy may be an effective complementary intervention for reducing anxiety in patients undergoing coronary angiography, although its effects on physiological parameters remain uncertain. Larger, high-quality randomized controlled trials are needed to confirm these findings.
- Open Access
- 10 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5410
Comparison of the Safety and Effectiveness of Apixaban Versus Rivaroxaban in Acute Venous Thromboembolism: A Propensity-Matched Real-World TriNetX Study with Obesity and Cancer Subgroup Analyses
Background: Apixaban and rivaroxaban are commonly used direct oral anticoagulants for venous thromboembolism (VTE), but comparative real-world effectiveness and safety data remain limited. Methods: We conducted a retrospective cohort study using the TriNetX database. Adults with VTE were stratified into apixaban and rivaroxaban treatment groups. Propensity score matching balanced baseline characteristics. Time-to-event outcomes up to 2 years were assessed using Kaplan–Meier analysis and Cox proportional hazards models. Results: Following propensity score matching, well-balanced cohorts (8247) were obtained, with a mean age of 58.3 ± 18.0 versus 57.3 ± 18.1 years. Recurrent VTE rates were broadly comparable at 3 months (22.14% vs. 22.26%; HR 1.02, 95% CI 0.95–1.09; p = 0.6, ARD −0.001, 95% CI: −0.014 to 0.011), with small but statistically significant increases observed with apixaban at 6-month (HR 1.07, 95% CI 1.01–1.13; p = 0.016, ARD 0.009, 95% CI: −0.005 to 0.023), 1-year (HR 1.07, 95% CI 1.01–1.12; p = 0.019, ARD 0.004, 95% CI: −0.010 to 0.019), and 2-year follow-ups (HR 1.08, 95% CI 1.04–1.13; p = 0.000, ARD −0.001, 95% CI: −0.013 to 0.011). All-cause mortality was comparable through 1 year; however, a statistically significant increase was observed at the 2-year follow-up for apixaban (HR 1.20, 95% CI 1.06–1.37; p = 0.005, ARD 0.005, 95% CI: −0.002 to 0.013). Bleeding outcomes were largely comparable in the overall cohort, with no statistically significant differences in composite major bleeding (2-year ARD: −0.004, 95% CI: −0.012–0.004), major bleeding (2-year ARD: 0.002, 95% CI: −0.004 to 0.007), gastrointestinal bleeding (2-year ARD: −0.001, 95% CI: −0.004–0.003), or intracerebral hemorrhage (2-year ARD: 0.000, 95% CI: −0.002–0.003) across follow-up periods. A statistically significant reduction in non-major bleeding with regard to apixaban was observed at the 6-month follow-up only (HR 0.79, 95% CI 0.63–0.98; p = 0.033) (2-year ARD: −0.004, 95% CI: −0.010–0.002). Subgroup analyses revealed important heterogeneity: among patients with obesity, composite major bleeding was significantly lower with respect to apixaban at the 2-year follow-up (HR 0.39, 95% CI 0.20–0.76; p = 0.004), whereas among patients with cancer, composite major bleeding was significantly higher with apixaban at the 1-year (HR 1.31, 95% CI 1.02–1.70; p = 0.037) and 2-year follow-ups (HR 1.32, 95% CI 1.04–1.68; p = 0.023). Conclusions: In this real-world propensity-matched analysis, apixaban and rivaroxaban demonstrated broadly comparable effectiveness and safety for VTE treatment, with largely similar bleeding outcomes in the overall cohort. Small but statistically significant increases in recurrent VTE and 2-year mortality with apixaban, alongside subgroup-specific bleeding differences, underscore the importance of individualized treatment selection based on patient-specific risk factors.
- 10 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5410
Open AccessComparison of the Safety and Effectiveness of Apixaban Versus Rivaroxaban in Acute Venous Thromboembolism: A Propensity-Matched Real-World TriNetX Study with Obesity and Cancer Subgroup Analyses
Background: Apixaban and rivaroxaban are commonly used direct oral anticoagulants for venous thromboembolism (VTE), but comparative real-world effectiveness and safety data remain limited. Methods: We conducted a retrospective cohort study using the TriNetX database. Adults with VTE were stratified into apixaban and rivaroxaban treatment groups. Propensity score matching balanced baseline characteristics. Time-to-event outcomes up to 2 years were assessed using Kaplan–Meier analysis and Cox proportional hazards models. Results: Following propensity score matching, well-balanced cohorts (8247) were obtained, with a mean age of 58.3 ± 18.0 versus 57.3 ± 18.1 years. Recurrent VTE rates were broadly comparable at 3 months (22.14% vs. 22.26%; HR 1.02, 95% CI 0.95–1.09; p = 0.6, ARD −0.001, 95% CI: −0.014 to 0.011), with small but statistically significant increases observed with apixaban at 6-month (HR 1.07, 95% CI 1.01–1.13; p = 0.016, ARD 0.009, 95% CI: −0.005 to 0.023), 1-year (HR 1.07, 95% CI 1.01–1.12; p = 0.019, ARD 0.004, 95% CI: −0.010 to 0.019), and 2-year follow-ups (HR 1.08, 95% CI 1.04–1.13; p = 0.000, ARD −0.001, 95% CI: −0.013 to 0.011). All-cause mortality was comparable through 1 year; however, a statistically significant increase was observed at the 2-year follow-up for apixaban (HR 1.20, 95% CI 1.06–1.37; p = 0.005, ARD 0.005, 95% CI: −0.002 to 0.013). Bleeding outcomes were largely comparable in the overall cohort, with no statistically significant differences in composite major bleeding (2-year ARD: −0.004, 95% CI: −0.012–0.004), major bleeding (2-year ARD: 0.002, 95% CI: −0.004 to 0.007), gastrointestinal bleeding (2-year ARD: −0.001, 95% CI: −0.004–0.003), or intracerebral hemorrhage (2-year ARD: 0.000, 95% CI: −0.002–0.003) across follow-up periods. A statistically significant reduction in non-major bleeding with regard to apixaban was observed at the 6-month follow-up only (HR 0.79, 95% CI 0.63–0.98; p = 0.033) (2-year ARD: −0.004, 95% CI: −0.010–0.002). Subgroup analyses revealed important heterogeneity: among patients with obesity, composite major bleeding was significantly lower with respect to apixaban at the 2-year follow-up (HR 0.39, 95% CI 0.20–0.76; p = 0.004), whereas among patients with cancer, composite major bleeding was significantly higher with apixaban at the 1-year (HR 1.31, 95% CI 1.02–1.70; p = 0.037) and 2-year follow-ups (HR 1.32, 95% CI 1.04–1.68; p = 0.023). Conclusions: In this real-world propensity-matched analysis, apixaban and rivaroxaban demonstrated broadly comparable effectiveness and safety for VTE treatment, with largely similar bleeding outcomes in the overall cohort. Small but statistically significant increases in recurrent VTE and 2-year mortality with apixaban, alongside subgroup-specific bleeding differences, underscore the importance of individualized treatment selection based on patient-specific risk factors.
- Open Access
- 17 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1368
Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis
Background: Heart failure patients are frequently prescribed SGLT2 inhibitors, but the incremental real-world benefit of adding GLP-1 receptor agonists is uncertain. Methods: A retrospective propensity-matched cohort study was conducted using the TriNetX Global Collaborative Network (171 healthcare organizations). Adults aged ≥18 years with incident heart failure who initiated either dual SGLT2 inhibitor and GLP-1 receptor agonist therapy or SGLT2 inhibitor monotherapy within 1 month of the first heart failure diagnosis were compared. Outcomes over 365 days included all-cause mortality, all-cause hospitalization, acute myocardial infarction, atrial fibrillation/flutter, acute kidney failure, pulmonary edema, new-onset diuretic use, urinary tract infection, retinopathy, and laboratory hypoglycemia (glucose ≤ 70 mg/dL). Cox proportional hazards models were used; the proportional hazards assumption was formally tested. Bonferroni and Benjamini–Hochberg adjustments were applied for multiple comparisons. E-values quantified robustness to unmeasured confounding. Appendicitis was used as a negative control outcome. Results: After 1:1 propensity score matching, 3421 patients were included in each cohort. Cohorts were well-balanced (all standardized mean differences < 0.10). Over 365 days of follow-up, no significant differences were observed between dual therapy and monotherapy in all-cause mortality (HR 0.92, 95% CI 0.77–1.09), all-cause hospitalization (HR 1.16, 95% CI 0.96–1.40), acute myocardial infarction (HR 1.20, 95% CI 0.92–1.55), atrial fibrillation/flutter (HR 1.05, 95% CI 0.85–1.30), acute kidney failure (HR 1.05, 95% CI 0.89–1.26), new-onset diuretic use (HR 0.92, 95% CI 0.78–1.09), or urinary tract infection (HR 1.16, 95% CI 0.90–1.48). Dual therapy was associated with a significant increase in retinopathy (HR 2.66, 95% CI 1.81–3.93; Bonferroni p = 0.001; E-value 4.77, lower CI bound 3.01), and a modest increase in laboratory hypoglycemia (HR 1.22, 95% CI 1.04–1.44) and pulmonary edema (HR 1.35, 95% CI 1.06–1.70), both of which survived FDR but not Bonferroni adjustment. Prespecified subgroup analyses showed lower mortality with dual therapy in patients aged 18–64 (HR 0.64, 95% CI 0.43–0.93) and in women (HR 0.60, 95% CI 0.45–0.81). The negative control outcome (appendicitis) was non-significant. Conclusions: In a propensity-matched real-world cohort with a conservative cohort definition, dual SGLT2 inhibitor and GLP-1 receptor agonist therapy was not associated with significant differences in mortality or major cardiovascular outcomes compared with SGLT2 inhibitor monotherapy. Subgroup signals favoring dual therapy in younger and female patients, alongside safety signals for retinopathy and laboratory hypoglycemia, are hypothesis-generating and should be confirmed in prospective trials.
- 17 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1368
Open AccessClinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis
Background: Heart failure patients are frequently prescribed SGLT2 inhibitors, but the incremental real-world benefit of adding GLP-1 receptor agonists is uncertain. Methods: A retrospective propensity-matched cohort study was conducted using the TriNetX Global Collaborative Network (171 healthcare organizations). Adults aged ≥18 years with incident heart failure who initiated either dual SGLT2 inhibitor and GLP-1 receptor agonist therapy or SGLT2 inhibitor monotherapy within 1 month of the first heart failure diagnosis were compared. Outcomes over 365 days included all-cause mortality, all-cause hospitalization, acute myocardial infarction, atrial fibrillation/flutter, acute kidney failure, pulmonary edema, new-onset diuretic use, urinary tract infection, retinopathy, and laboratory hypoglycemia (glucose ≤ 70 mg/dL). Cox proportional hazards models were used; the proportional hazards assumption was formally tested. Bonferroni and Benjamini–Hochberg adjustments were applied for multiple comparisons. E-values quantified robustness to unmeasured confounding. Appendicitis was used as a negative control outcome. Results: After 1:1 propensity score matching, 3421 patients were included in each cohort. Cohorts were well-balanced (all standardized mean differences < 0.10). Over 365 days of follow-up, no significant differences were observed between dual therapy and monotherapy in all-cause mortality (HR 0.92, 95% CI 0.77–1.09), all-cause hospitalization (HR 1.16, 95% CI 0.96–1.40), acute myocardial infarction (HR 1.20, 95% CI 0.92–1.55), atrial fibrillation/flutter (HR 1.05, 95% CI 0.85–1.30), acute kidney failure (HR 1.05, 95% CI 0.89–1.26), new-onset diuretic use (HR 0.92, 95% CI 0.78–1.09), or urinary tract infection (HR 1.16, 95% CI 0.90–1.48). Dual therapy was associated with a significant increase in retinopathy (HR 2.66, 95% CI 1.81–3.93; Bonferroni p = 0.001; E-value 4.77, lower CI bound 3.01), and a modest increase in laboratory hypoglycemia (HR 1.22, 95% CI 1.04–1.44) and pulmonary edema (HR 1.35, 95% CI 1.06–1.70), both of which survived FDR but not Bonferroni adjustment. Prespecified subgroup analyses showed lower mortality with dual therapy in patients aged 18–64 (HR 0.64, 95% CI 0.43–0.93) and in women (HR 0.60, 95% CI 0.45–0.81). The negative control outcome (appendicitis) was non-significant. Conclusions: In a propensity-matched real-world cohort with a conservative cohort definition, dual SGLT2 inhibitor and GLP-1 receptor agonist therapy was not associated with significant differences in mortality or major cardiovascular outcomes compared with SGLT2 inhibitor monotherapy. Subgroup signals favoring dual therapy in younger and female patients, alongside safety signals for retinopathy and laboratory hypoglycemia, are hypothesis-generating and should be confirmed in prospective trials.
- 25 May 2026
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (6) , 607-619
Combination pitavastatin–ezetimibe therapy for hypercholesterolemia and mixed dyslipidemia: a systematic review and meta-analysis
1. Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, with dyslipidemia being an important modifiable risk factor [1]. Elevated low-density lipoprotein cholestero...
- 25 May 2026
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (6) , 607-619
Combination pitavastatin–ezetimibe therapy for hypercholesterolemia and mixed dyslipidemia: a systematic review and meta-analysis
1. Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, with dyslipidemia being an important modifiable risk factor [1]. Elevated low-density lipoprotein cholestero...
- Open Access
- 23 May 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (6) , 222
Cardiovascular Outcomes with Colchicine in Coronary Artery Disease and HFpEF: A Propensity-Matched TriNetX Analysis
Background: Coronary artery disease (CAD) and heart failure with preserved ejection fraction (HFpEF) are major causes of morbidity and mortality. Systemic inflammation contributes to both, suggesting potential benefit from colchicine, though data in CAD-HFpEF are limited. Methods: We conducted a real-world study using the TriNetX Research Network, identifying 480,434 adults with CAD and HFpEF. Patients were categorized as colchicine users (n = 30,254) or non-users (n = 450,180). One-to-one propensity score matching yielded 28,941 patients per group. The primary outcome was a composite of acute myocardial infarction, stroke, all-cause mortality, and acute heart failure. Secondary outcomes included individual components, hospitalizations, atrial fibrillation, and gastrointestinal events, assessed at 1- and 3-year follow-up. Results: At 1 year, the primary outcome occurred in 16.9% of the colchicine group versus 19.8% of non-users (HR: 0.86, 95% CI: 0.81–0.91; p < 0.001). All-cause mortality was 11.4% versus 14.5% (HR: 0.77, 95% CI: 0.73–0.80; p < 0.001). At 3 years, the primary outcome occurred in 34.2% versus 39.7% (HR: 0.88, 95% CI: 0.85–0.92; p < 0.001), with acute heart failure slightly higher in the colchicine group (27.5% vs. 26.5%; HR: 1.04, 95% CI: 1.01–1.08; p = 0.009). Stroke was modestly reduced (HR: 0.93, 95% CI: 0.88–0.99; p = 0.014). No significant differences were seen in all-cause hospitalization, atrial fibrillation, or gastrointestinal events. Conclusions: In patients with CAD and HFpEF, colchicine was associated with lower short- and medium-term risk of composite cardiovascular events and mortality, with modest attenuation over time, suggesting early time-dependent association rather than sustained structural effects. Prospective randomized trials are warranted.
- 23 May 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (6) , 222
Open AccessCardiovascular Outcomes with Colchicine in Coronary Artery Disease and HFpEF: A Propensity-Matched TriNetX Analysis
Background: Coronary artery disease (CAD) and heart failure with preserved ejection fraction (HFpEF) are major causes of morbidity and mortality. Systemic inflammation contributes to both, suggesting potential benefit from colchicine, though data in CAD-HFpEF are limited. Methods: We conducted a real-world study using the TriNetX Research Network, identifying 480,434 adults with CAD and HFpEF. Patients were categorized as colchicine users (n = 30,254) or non-users (n = 450,180). One-to-one propensity score matching yielded 28,941 patients per group. The primary outcome was a composite of acute myocardial infarction, stroke, all-cause mortality, and acute heart failure. Secondary outcomes included individual components, hospitalizations, atrial fibrillation, and gastrointestinal events, assessed at 1- and 3-year follow-up. Results: At 1 year, the primary outcome occurred in 16.9% of the colchicine group versus 19.8% of non-users (HR: 0.86, 95% CI: 0.81–0.91; p < 0.001). All-cause mortality was 11.4% versus 14.5% (HR: 0.77, 95% CI: 0.73–0.80; p < 0.001). At 3 years, the primary outcome occurred in 34.2% versus 39.7% (HR: 0.88, 95% CI: 0.85–0.92; p < 0.001), with acute heart failure slightly higher in the colchicine group (27.5% vs. 26.5%; HR: 1.04, 95% CI: 1.01–1.08; p = 0.009). Stroke was modestly reduced (HR: 0.93, 95% CI: 0.88–0.99; p = 0.014). No significant differences were seen in all-cause hospitalization, atrial fibrillation, or gastrointestinal events. Conclusions: In patients with CAD and HFpEF, colchicine was associated with lower short- and medium-term risk of composite cardiovascular events and mortality, with modest attenuation over time, suggesting early time-dependent association rather than sustained structural effects. Prospective randomized trials are warranted.
- Open Access
- 14 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1108
Comparative Effectiveness of Finerenone Versus SGLT2 Inhibitors in Patients with HFpEF and CKD: A Real-World Propensity-Matched TriNetX Analysis
Background: Finerenone and sodium–glucose cotransporter-2 inhibitors provide cardiovascular and renal benefits in patients with chronic kidney disease (CKD) and heart failure (HF), but real-world comparative evidence is limited. Methods: This retrospective study used the TriNetX database. Adults ≥ 40 years with CKD stages 1–5 and HF [LVEF > 40%; excluding end-stage renal disease (ESRD) or dialysis] receiving finerenone were compared with those on SGLT2 inhibitors. Propensity score matching (1:1) yielded 333 patients per cohort. Kaplan–Meier and Cox models estimated hazard ratios (HRs) with 95% confidence intervals. Results: After matching, baseline characteristics were reasonably balanced, with some residual imbalance remaining. All-cause mortality was similar between finerenone and SGLT2 inhibitors at 6 months (HR 0.98; 95% CI 0.50–1.90) and 1 year (HR 0.93; 95% CI 0.53–1.66). All-cause hospitalization or ER visits were also comparable at 6 months (HR 1.07; 95% CI 0.84–1.36) and 1 year (HR 1.04; 95% CI 0.83–1.29). Finerenone was associated with a modest, borderline reduction in HF hospitalization at 1 year, without consistent effects across timepoints or a mortality benefit; thus, this finding is hypothesis-generating (HR 0.81; 95% CI 0.66–0.99). Safety outcomes were similar between groups. Conclusions: In this real-world analysis, finerenone was associated with similar all-cause mortality, overall hospitalization, and renal safety outcomes compared with SGLT2 inhibitors, with a modest reduction in HF hospitalization at 1 year that should be interpreted cautiously given the exploratory nature of the study. These findings are hypothesis-generating and underscore the need for prospective head-to-head trials to better define optimal therapy sequencing in patients with HFpEF and CKD.
- 14 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1108
Open AccessComparative Effectiveness of Finerenone Versus SGLT2 Inhibitors in Patients with HFpEF and CKD: A Real-World Propensity-Matched TriNetX Analysis
Background: Finerenone and sodium–glucose cotransporter-2 inhibitors provide cardiovascular and renal benefits in patients with chronic kidney disease (CKD) and heart failure (HF), but real-world comparative evidence is limited. Methods: This retrospective study used the TriNetX database. Adults ≥ 40 years with CKD stages 1–5 and HF [LVEF > 40%; excluding end-stage renal disease (ESRD) or dialysis] receiving finerenone were compared with those on SGLT2 inhibitors. Propensity score matching (1:1) yielded 333 patients per cohort. Kaplan–Meier and Cox models estimated hazard ratios (HRs) with 95% confidence intervals. Results: After matching, baseline characteristics were reasonably balanced, with some residual imbalance remaining. All-cause mortality was similar between finerenone and SGLT2 inhibitors at 6 months (HR 0.98; 95% CI 0.50–1.90) and 1 year (HR 0.93; 95% CI 0.53–1.66). All-cause hospitalization or ER visits were also comparable at 6 months (HR 1.07; 95% CI 0.84–1.36) and 1 year (HR 1.04; 95% CI 0.83–1.29). Finerenone was associated with a modest, borderline reduction in HF hospitalization at 1 year, without consistent effects across timepoints or a mortality benefit; thus, this finding is hypothesis-generating (HR 0.81; 95% CI 0.66–0.99). Safety outcomes were similar between groups. Conclusions: In this real-world analysis, finerenone was associated with similar all-cause mortality, overall hospitalization, and renal safety outcomes compared with SGLT2 inhibitors, with a modest reduction in HF hospitalization at 1 year that should be interpreted cautiously given the exploratory nature of the study. These findings are hypothesis-generating and underscore the need for prospective head-to-head trials to better define optimal therapy sequencing in patients with HFpEF and CKD.
- Open Access
- 14 January 2026
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 8, ojag085
Efficacy and Safety of IncobotulinumtoxinA for the Simultaneous Treatment of Upper Facial Lines: A GRADE Assessed Systematic Review and Meta-analysis
Background: Upper facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment; yet, comprehensive synthesized evidence is limited. Objectives: To systematically evaluate the efficacy and safety of IncobotulinumtoxinA compared with placebo for the simultaneous treatment of UFLs in adults, following PRISMA 2020 guidelines. Methods: Comprehensive searches of PubMed, Embase, Cochrane CENTRAL, ICTRP, and ClinicalTrials.gov were performed to identify randomized controlled trials (RCTs) evaluating IncobotulinumtoxinA for combined UFLs treatment. The primary outcome was ≥1-grade improvement on Day 30. Secondary outcomes included ≥2-grade improvement and Global Aesthetic Improvement Scale (GAIS) scores. Safety outcomes included adverse events (AEs), treatment-emergent adverse events (TEAEs), and headaches. Results: Three RCTs (n = 704) were included. Pooled analysis using random-effects model demonstrated a significant ≥1-grade improvement at Day 30 in IncobotulinumtoxinA compared with placebo across all regions: GFLs (RR 21.49, 95% CI: 9.89-46.73), HFLs (RR 19.17, 95% CI: 9.23-39.80), and LCLs (RR 11.68, 95% CI: 7.49-18.20), all P < .00001. A ≥ 2-grade improvement similarly favored treatment across all areas (RRs 76.26-115.04; all P < .00001). Investigator-assessed GAIS scores also improved significantly (MD 2.29, 95% CI: 2.11-2.46, P < .00001). Serious AEs were lower with IncobotulinumtoxinA (RR 0.14, P = .03). There was no significant difference in TEAEs and headaches from placebo. Conclusions: IncobotulinumtoxinA demonstrates statistically significant efficacy and a comparable safety profile vs placebo for simultaneous UFLs treatment. These findings support its use in aesthetic practice, warranting further long-term investigation. Level of Evidence: 1 (Therapeutic): For image description, please refer to the figure legend and surrounding text.
- 14 January 2026
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 8, ojag085
Open AccessEfficacy and Safety of IncobotulinumtoxinA for the Simultaneous Treatment of Upper Facial Lines: A GRADE Assessed Systematic Review and Meta-analysis
Background: Upper facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment; yet, comprehensive synthesized evidence is limited. Objectives: To systematically evaluate the efficacy and safety of IncobotulinumtoxinA compared with placebo for the simultaneous treatment of UFLs in adults, following PRISMA 2020 guidelines. Methods: Comprehensive searches of PubMed, Embase, Cochrane CENTRAL, ICTRP, and ClinicalTrials.gov were performed to identify randomized controlled trials (RCTs) evaluating IncobotulinumtoxinA for combined UFLs treatment. The primary outcome was ≥1-grade improvement on Day 30. Secondary outcomes included ≥2-grade improvement and Global Aesthetic Improvement Scale (GAIS) scores. Safety outcomes included adverse events (AEs), treatment-emergent adverse events (TEAEs), and headaches. Results: Three RCTs (n = 704) were included. Pooled analysis using random-effects model demonstrated a significant ≥1-grade improvement at Day 30 in IncobotulinumtoxinA compared with placebo across all regions: GFLs (RR 21.49, 95% CI: 9.89-46.73), HFLs (RR 19.17, 95% CI: 9.23-39.80), and LCLs (RR 11.68, 95% CI: 7.49-18.20), all P < .00001. A ≥ 2-grade improvement similarly favored treatment across all areas (RRs 76.26-115.04; all P < .00001). Investigator-assessed GAIS scores also improved significantly (MD 2.29, 95% CI: 2.11-2.46, P < .00001). Serious AEs were lower with IncobotulinumtoxinA (RR 0.14, P = .03). There was no significant difference in TEAEs and headaches from placebo. Conclusions: IncobotulinumtoxinA demonstrates statistically significant efficacy and a comparable safety profile vs placebo for simultaneous UFLs treatment. These findings support its use in aesthetic practice, warranting further long-term investigation. Level of Evidence: 1 (Therapeutic): For image description, please refer to the figure legend and surrounding text.